Tango Therapeutics (TNGX)
NASDAQ:TNGX
Want to see TNGX full AI Analyst Report?
Total Valuation
Tango Therapeutics has a market cap or net worth of $2.98B. The enterprise value is $2.23B.
Market Cap$2.98B
Enterprise Value$2.23B
Share Statistics
Tango Therapeutics has 144,647,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding144,647,980
Owned by Insiders10.98%
Owned by Institutions10.88%
Financial Efficiency
Tango Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -29.31%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-29.31%
Return on Capital Employed (ROCE)-0.30
Revenue Per Employee402.48K
Profits Per Employee-655.45K
Employee Count155
Asset Turnover0.16
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tango Therapeutics is ―. Tango Therapeutics’s PEG ratio is 0.38.
PE Ratio―
PS Ratio16.50
PB Ratio2.97
Price to Fair Value2.97
Price to FCF-7.36
Price to Operating Cash Flow-20.59
PEG Ratio0.38
Income Statement
In the last 12 months, Tango Therapeutics had revenue of 62.38M and earned -101.59M in profits. Earnings per share was -0.87.
Revenue62.38M
Gross Profit60.10M
Operating Income-111.29M
Pretax Income-101.59M
Net Income-101.59M
EBITDA-109.01M
Earnings Per Share (EPS)-0.87
Cash Flow
In the last 12 months, operating cash flow was -141.55M and capital expenditures -995.00K, giving a free cash flow of -142.54M billion.
Operating Cash Flow-141.55M
Free Cash Flow-142.54M
Free Cash Flow per Share-0.99
Dividends & Yields
Tango Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.31
52-Week Price Change974.07%
50-Day Moving Average21.83
200-Day Moving Average12.40
Relative Strength Index (RSI)40.82
Average Volume (3m)3.04M
Important Dates
Tango Therapeutics upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Tango Therapeutics as a current ratio of 16.32, with Debt / Equity ratio of 8.37%
Current Ratio16.32
Quick Ratio16.32
Debt to Market Cap0.03
Net Debt to EBITDA0.72
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tango Therapeutics has paid 4.00K in taxes.
Income Tax4.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Tango Therapeutics EV to EBITDA ratio is -8.72, with an EV/FCF ratio of -6.79.
EV to Sales15.24
EV to EBITDA-8.72
EV to Free Cash Flow-6.79
EV to Operating Cash Flow-6.84
Balance Sheet
Tango Therapeutics has $379.84M in cash and marketable securities with $32.79M in debt, giving a net cash position of $347.05M billion.
Cash & Marketable Securities$379.84M
Total Debt$32.79M
Net Cash$347.05M
Net Cash Per Share$2.40
Tangible Book Value Per Share$2.98
Margins
Gross margin is 97.25%, with operating margin of -178.39%, and net profit margin of -162.85%.
Gross Margin97.25%
Operating Margin-178.39%
Pretax Margin-162.85%
Net Profit Margin-162.85%
EBITDA Margin-174.74%
EBIT Margin-178.39%
Analyst Forecast
The average price target for Tango Therapeutics is $30.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$30.70
Price Target Upside15.24% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast39.04%
EPS Growth Forecast32.40%